There are 2789 resources available
511TiP - A phase III, multicenter, open-label, randomized study to assess the efficacy and safety of cetuximab plus capecitabine versus cetuximab as maintenance treatment following first-line induction treatment with FOLFOX and cetuximab in Chinese patients with RAS and BRAF WT mCRC
Presenter: Dongsheng Zhang
Session: ePoster Display
521P - Dose escalation study of two different alternative dosing schedules of tusamitamab ravtansine (tusa, SAR408701) in patients (pts) with advanced solid tumors
Presenter: Maria Vieito
Session: ePoster Display
522P - Risk mitigation of ocular toxicities due to antibody drug conjugates (ADCs) in novel early-phase clinical trials
Presenter: Khobe Chandran
Session: ePoster Display
523P - AFP-maytansine conjugate: A novel targeted cancer immunotherapy
Presenter: Igor Sherman
Session: ePoster Display
524P - A phase I, open-label, dose-escalation trial of BI 1701963 in patients (pts) with KRAS mutated solid tumours: A snapshot analysis
Presenter: Melissa Johnson
Session: ePoster Display
525P - Efficacy, safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from phase I dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients (pts) with advanced and metastatic solid tumors
Presenter: Meredith Mckean
Session: ePoster Display
526P - Pharmacodynamic evidence for WEE1 target engagement in surrogate and tumor tissues from a phase I study of the WEE1 inhibitor ZN-c3
Presenter: Pavani Chalasani
Session: ePoster Display
527P - Phase I study of the novel prodrug MIV-818 in patients with hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA) or liver metastases (LM)
Presenter: Debashis Sarker
Session: ePoster Display
528P - Discovery of ZN-d5, a potent BCL-2 inhibitor with improved selectivity for BCL-2
Presenter: Joseph Pinchman
Session: ePoster Display